Actively Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Led by Merck Sharp & Dohme LLC · Updated on 2026-05-01
32
Participants Needed
13
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
CONDITIONS
Official Title
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have recurrent low-grade (Ta) Non-Muscle Invasive Bladder Cancer (NMIBC) in the bladder
- Have visible tumor confirmed by cystoscopy within 12 weeks before first dose
- Have intermediate-risk NMIBC defined by one or more of the following: multiple tumors, more than one occurrence of low-grade NMIBC within 1 year, early recurrence of low-grade disease within 1 year, solitary tumor larger than 3 cm, or failure of prior intravesical treatment
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 14 days before first dose
You will not qualify if you...
- Have newly diagnosed low-grade non-muscle invasive bladder cancer (Ta NMIBC) in the bladder
- Have past or current history of high-grade (Ta or T1 or CIS) NMIBC, muscle invasive bladder cancer, or metastatic urothelial carcinoma
- Have a condition that prevents normal voiding or requires holding bladder voiding for 1 to 2 hours
- Have history of severe dry eye syndrome, severe Meibomian gland disease, blepharitis, or severe corneal disease preventing or delaying corneal healing
- Have active inflammatory bowel disease requiring immunosuppressive medication or prior history of inflammatory bowel disease such as Crohn's disease or ulcerative colitis
- Have uncontrolled significant cardiovascular or cerebrovascular disease
- Have a known progressing additional malignancy or one treated actively within the past 3 years
- Have history of noninfectious pneumonitis or interstitial lung disease requiring steroids, or current pneumonitis or interstitial lung disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Michael G Oefelein Clinical Trials ( Site 0053)
Bakersfield, California, United States, 93301
Actively Recruiting
2
Moffitt Cancer Center ( Site 0057)
Tampa, Florida, United States, 33612
Actively Recruiting
3
Northwestern University ( Site 0051)
Chicago, Illinois, United States, 60611
Actively Recruiting
4
Johns Hopkins University ( Site 0055)
Baltimore, Maryland, United States, 21287
Actively Recruiting
5
Princess Margaret Cancer Centre ( Site 0003)
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
6
CIUSSS de l'Estrie-CHUS ( Site 0002)
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
7
Hôpital Claude Huriez ( Site 0012)
Lille, Nord, France, 59037
Actively Recruiting
8
HENRI MONDOR HOSPITAL ( Site 0011)
Créteil, Val-de-Marne, France, 94010
Actively Recruiting
9
Gustave Roussy ( Site 0013)
Villejuif, Val-de-Marne, France, 94805
Actively Recruiting
10
Erasmus Medisch Centrum ( Site 0032)
Rotterdam, South Holland, Netherlands, 3015 GD
Actively Recruiting
11
Hospital Universitario Virgen de la Victoria ( Site 0043)
Málaga, Andalusia, Spain, 29010
Actively Recruiting
12
Hospital Universitario 12 de Octubre ( Site 0042)
Madrid, Spain, 28041
Actively Recruiting
13
St Bartholomew s Hospital ( Site 0061)
London, London, City of, United Kingdom, EC1A 7BE
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here